Teva Pharmaceutical Industries Pre-Tax Profit Margin 2010-2024 | TEVA
Current and historical pre-tax profit margin for Teva Pharmaceutical Industries (TEVA) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Teva Pharmaceutical Industries pre-tax profit margin for the three months ending September 30, 2024 was .
| Teva Pharmaceutical Industries Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$16.77B |
$-0.53B |
-3.16% |
| 2024-06-30 |
$16.29B |
$-0.14B |
-0.87% |
| 2024-03-31 |
$16.00B |
$-0.82B |
-5.12% |
| 2023-12-31 |
$15.85B |
$-0.62B |
-3.94% |
| 2023-09-30 |
$15.27B |
$-2.33B |
-15.25% |
| 2023-06-30 |
$15.02B |
$-2.23B |
-14.83% |
| 2023-03-31 |
$14.93B |
$-2.46B |
-16.51% |
| 2022-12-31 |
$14.93B |
$-3.16B |
-21.19% |
| 2022-09-30 |
$15.14B |
$-2.14B |
-14.14% |
| 2022-06-30 |
$15.43B |
$-1.93B |
-12.47% |
| 2022-03-31 |
$15.56B |
$-0.46B |
-2.94% |
| 2021-12-31 |
$15.88B |
$0.66B |
4.14% |
| 2021-09-30 |
$16.23B |
$0.97B |
5.98% |
| 2021-06-30 |
$16.32B |
$-3.87B |
-23.71% |
| 2021-03-31 |
$16.28B |
$-4.23B |
-25.97% |
| 2020-12-31 |
$16.66B |
$-4.41B |
-26.45% |
| 2020-09-30 |
$16.67B |
$-4.58B |
-27.48% |
| 2020-06-30 |
$16.79B |
$-0.42B |
-2.47% |
| 2020-03-31 |
$17.10B |
$-1.21B |
-7.10% |
| 2019-12-31 |
$16.89B |
$-1.27B |
-7.49% |
| 2019-09-30 |
$16.40B |
$-4.61B |
-28.14% |
| 2019-06-30 |
$16.83B |
$-4.53B |
-26.94% |
| 2019-03-31 |
$17.36B |
$-3.93B |
-22.67% |
| 2018-12-31 |
$18.27B |
$-2.60B |
-14.21% |
| 2018-09-30 |
$19.69B |
$-12.42B |
-63.05% |
| 2018-06-30 |
$20.78B |
$-12.09B |
-58.15% |
| 2018-03-31 |
$21.80B |
$-17.81B |
-81.71% |
| 2017-12-31 |
$22.39B |
$-18.38B |
-82.10% |
| 2017-09-30 |
$23.48B |
$-6.09B |
-25.92% |
| 2017-06-30 |
$23.43B |
$-5.59B |
-23.86% |
| 2017-03-31 |
$22.74B |
$0.65B |
2.84% |
| 2016-12-31 |
$21.90B |
$0.82B |
3.76% |
| 2016-09-30 |
$20.29B |
$2.60B |
12.81% |
| 2016-06-30 |
$19.55B |
$2.30B |
11.75% |
| 2016-03-31 |
$19.48B |
$2.66B |
13.67% |
| 2015-12-31 |
$19.65B |
$2.35B |
11.97% |
| 2015-09-30 |
$19.94B |
$2.36B |
11.85% |
| 2015-06-30 |
$20.17B |
$3.08B |
15.26% |
| 2015-03-31 |
$20.25B |
$3.30B |
16.31% |
| 2014-12-31 |
$20.27B |
$3.64B |
17.95% |
| 2014-09-30 |
$20.53B |
$3.27B |
15.91% |
| 2014-06-30 |
$20.54B |
$2.96B |
14.43% |
| 2014-03-31 |
$20.41B |
$1.44B |
7.06% |
| 2013-12-31 |
$20.31B |
$1.25B |
6.15% |
| 2013-09-30 |
$20.13B |
$0.93B |
4.63% |
| 2013-06-30 |
$20.05B |
$0.08B |
0.37% |
| 2013-03-31 |
$20.12B |
$1.66B |
8.25% |
| 2012-12-31 |
$20.32B |
$1.82B |
8.95% |
| 2012-09-30 |
$20.74B |
$2.18B |
10.49% |
| 2012-06-30 |
$20.12B |
$3.28B |
16.30% |
| 2012-03-31 |
$19.33B |
$2.99B |
15.44% |
| 2011-12-31 |
$18.31B |
$2.96B |
16.14% |
| 2011-09-30 |
$17.05B |
$3.14B |
18.42% |
| 2011-06-30 |
$16.96B |
$3.36B |
19.80% |
| 2011-03-31 |
$16.55B |
$3.67B |
22.17% |
| 2010-12-31 |
$16.12B |
$3.65B |
22.62% |
| 2010-09-30 |
$15.51B |
$3.31B |
21.32% |
| 2010-06-30 |
$14.81B |
$2.82B |
19.05% |
| 2010-03-31 |
$14.41B |
$2.54B |
17.60% |
| 2009-12-31 |
$13.90B |
$2.20B |
15.85% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.044B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
